If true, apical TfR could serve as a targeting molecule in the design of specific drug delivery vehicles for the treatment of IBD, owing to its location at the inflamed sites and the possibility that it may trigger endocytosis upon ligation. This evidence concerns the gene TFRC and inflammatory bowel disease.